clinical trial · NCT04576949
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
Achieve Life Sciences·phase3·completed·n = 810
Smoking CessationCytisiniclinePlaceboBehavioral support
brief summary
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
started
Oct 13, 2020
primary completion
Dec 23, 2021
completion
Dec 23, 2021
last updated
Jan 15, 2026
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline in Adult Smokers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol